Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial
Broker upgrades odds on AVANZAR lung cancer trial after arguing repeated delays signal strong results in treatment arm Jefferies has…
92,830$
0,26%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop
Exxon Mobil, Palantir and AstraZeneca lead Zacks latest analyst reports, highlighting strong production growth, AI momentum and a robust drug…
Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca
Exxon Mobil leads fresh analyst reports as Permian and Guyana output power growth, while Palantirs AI platforms and AstraZenecas drug…
SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript
Image source: The Motley Fool.DATEMarch 3, 2026, 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Jurgi CamblongChief Financial Officer — George…
Salesforce CEO touts company resilience amid software slump
Looking back, it almost seems like a dream. On Aug. 31, 2020, the U.S. had just surpassed six million COVID-19…
LNTH: 2025 Earnings Flash Report
By John Vandermosten, CFANASDAQ:LNTHLantheus Reports 2025 Financial and Operational Results Lantheus Holdings, Inc. (NASDAQ:LNTH) reported financial results yesterday. Revenue was…
AstraZeneca has sector leading replacement power to cope with 2030 patent cliff
The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS,...…
Arcus (RCUS) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEWednesday, Feb. 25, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Terry J. RosenPresident —…
IonQ (IONQ) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DateFeb. 25, 2026 at 4:30 p.m. ETCall participantsChairman and Chief Executive Officer — Niccolo de MasiChief…
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
AZNs stronger growth outlook and 2030 revenue target may outshine PFEs yield and cheaper valuation.…
Fixed-duration Calquence combo approved in US
20 February 2026Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in…
Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor
In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured a Federal…
Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor
In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured a Federal…
Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer
Lund, Sweden — 17 February 2026 — Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed…
Notable healthcare headlines for the week: AstraZeneca, CVS Health, and Moderna in focus
…
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory
Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to hold from buy, citing a less favourable earnings trajectory as the drugmaker...…
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory
Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to hold from buy, citing a less favourable earnings trajectory as the drugmaker...…
Citi maintains buy on AstraZeneca with £170 target, cites sector-best pipeline
Double-digit earnings outlook and strong trial momentum support top pick status AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) remains a top pick at…
Citi maintains buy on AstraZeneca with £170 target, cites sector-best pipeline
Double-digit earnings outlook and strong trial momentum support top pick status AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) remains a top pick at…
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
…